ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Biohaven hobbled by contractor’s warning letter

by Rick Mullin
July 26, 2019 | APPEARED IN VOLUME 97, ISSUE 30

 

The US Food and Drug Administration’s review of Biohaven Pharmaceutical’s Nurtec, a treatment for amyotrophic lateral sclerosis, has been delayed because of problems with the active pharmaceutical ingredient, riluzole,supplied between 2014 and 2016 by Apotex Pharmachem India. Biohaven learned of the FDA’s concerns in a recent letter. It says Apotex did not communicate the concerns, contained in an earlier warning letter, during a bioequivalence trial and the submission of a new drug application. Biohaven is sourcing riluzole for commercial production from another supplier.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment